Treatment costs of prostate cancer in the first year after diagnosis: A short-term cost of illness study for France, Germany, Italy, Spain and the UK

BJU International

Volumn 105, Issue 1, 2010, Pages 49-56

  Fourcade, Richard Olivier ^a   Benedict, Ágnes ^b   Black, Libby K ^c   Stokes, Michael E ^d   Alcaraz, Antonio ^e   Castro, Ramiro ^f,g  

^a Service DUrologie Centre Hospitalier Auxerre   (France)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNITED BIOSOURCE CORPORATION   (Canada)

^e HOSPITAL CLÍNIC   (Spain)

^f Urology Center of Excellence Research   (Spain)

^g NONE

Author keywords

Cost of illness; Europe; Prostate cancer

Indexed keywords

DOCETAXEL;

ADULT; AGED; AGING; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL STUDY; COST OF ILLNESS; DATA BASE; FRANCE; GERMANY; HORMONAL THERAPY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; SPAIN; SURVIVAL; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; EUROPE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 72149111425     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08716.x     Document Type: Article

References (50)

1. Ferlay J, Autire P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 18 : 581 592 (Pubitemid 46359643)
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995 273 : 548 552
3. Roemeling S, Roobol MJ, Gosselaar C, Schröder FH. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Prostate 2006 66 : 1076 1081
4. Hussain S, Gunnell D, Donovan J et al. Secular trends in prostate cancer mortality, incidence and treatment in England and Wales, 1975-2004. BJU Int 2008 101 : 547 555
5. Kvåle R, Auvinen A, Adami HO et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007 19 : 1881 1887
6. Berrino F, De Angelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007 8 : 773 783
7. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007 8 : 784 796 (Pubitemid 47321601)
8. Collin SM, Martin RM, Metcalfe C et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008 9 : 445 452
9. Bartsch G, Horninger W, Klocker H et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Intl 2008 101 : 809 816
10. Heidenreich A, Aus G, Bolla M et al. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008 53 : 68 80
11. BAUS. BAUS Cancer Registry Analyses of minimum data set for urological cancers for 1 January-31 December 2005. 2006
12. Klatte T, Klatte D, Böhm M, Allhoff EP. Die Skelettszintigraphie beim neu diagnostizierten Prostatakarzinom. Klinische Aspekte und Kostenanalyse. Urologe A 2006 45 : 1293 1299
13. Herranz Amo F, Arrizabalaga Moreno M, Carballido Rodríguez JA et al. El cáncer de Próstata en la Comunidad de Madrid en el año 2000. I - Incidencia. Actas Urol Esp 2003 27 : 323 334 (Pubitemid 36827973)
14. Herranz Amo F, Arrizabalaga Moreno M, Carballido Rodríguez JA et al. El cáncer de Próstata en la Comunidad de Madrid en el año 2000. II - Presentación y diagnóstico. Actas Urol Esp 2003 27 : 335 344 (Pubitemid 36827974)
15. Herranz Amo F, Arrizabalaga Moreno M, Carballido Rodríguez JA et al. El cáncer de Próstata en la Comunidad de Madrid en el año 2000. IV - Tratamiento. Actas Urol Esp 2003 27 : 418 427 (Pubitemid 36898413)
16. Lazzaro C. Managing patients with prostate cancer in Italy during the first year after diagnosis. A cost description based on a sample of 8 urological wards. Arch Ital Urol Androl 2003 75 : 138 149
17. British National Formulary (BNF): 52. Available at: http://www.bnf.org. Accessed October 2008
18. The Chartered Institute of Public Finance Accountancy (CIPFA). The Health Service Database 2001 (Financial Year 2002-2003). London : CIPFA/HFM, IPF
19. Personal Social Services Research Unit (PSSRU). University of Kent, Unit Costs for Health and Social Care 2006. Available at: http://www.pssru.ac.uk/pdf/ uc/uc2006/uc2006.pdf. Accessed October 2008
20. Newcastle Upon Tyne NHS Trusts. Diagnostic Service, Tariffs 2006/07. Available at: http://www.newcastle-hospitals.org.uk/directorates/finance/ diagnostic-service-tariffs. Accessed October 2008
21. Department of Health. National Schedule of Reference Costs 2005-06, for NHS Trust & PCT Combined. Available at: http://www.dh.gov.uk/en/ PublicationsandStatistics/Publications/PublicationsPolicyandGuidance/DH-062884. Accessed June 2009
22. Department of Health. National Schedule of Reference Costs 2006/7 for NHS Trust & PCT Combined. Available at: http://www.dh.gov.uk/en/ PublicationsandStatistics/Publications/PublicationsandGuidance/DH-082571. Accessed June 2009
23. Vidal Expert, la formule enrichie CD
24. NABM. Nomenclature des Actes de Biologie Médicale. Available at: http://www.ameli.fr. Accessed October 2008
25. CCAM. Classification Commune des Actes Médicaux. Available at: http://www.ameli.fr. Accessed October 2008
26. Echelle nationale de coûts '2005a'-public hospitals. Available at: http://www.atih.sante.fr. Accessed October 2008
27. APHP-1999. Assistance Publique Hôpitaux de Paris
28. Buron C, Le Vu B, Cosset JM et al. Brachytherapy versus Prostatectomy in localized prostate cancer: results of a French multicenter prospective Medico-Economic study. Int J Radiat Oncol Biol Phys 2007 67 : 818 822
29. Institut National de la Statistique et des Etudes Economiques. Paris 2007 Institut, July 2006. Available at: http://www.insee.fr/fr/home/home-page.asp. Accessed October 2008
30. Die Rote Liste Online. Arzneimittel-Informationene für Ärzte und Apotheker. Available at: http://www.roteliste.de/Online. Accessed July 2006
31. Fallpauschalenkatalog 2006. Available at: http://www.g-drg.de/cms/index. php/inek-site-de/Archiv/Systemjahr-2008-bzw.-Datenjahr-2006#sm2. Accessed October 2008
32. Agenzia Italiana del Farmaco. Prontuario Farmaceutico Nazionale. Available at: http://www.agenziafarmaco.it/ATTIVITA-EDITORIALE/sectionfcc0.html. Accessed June 2009
33. NHS. Tariff 2006. Available at: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-4127649. Accessed October 2008
34. Lucioni C, Garancini MP, Massi-Beneditti M, Massi S, Serra G. CODE-2 study, Social cost of diabetes type II in Italy. Pharmacoeconomics 2000 2 : 1 21
35. Quaglini S, Cavallini A, Gerzeli S, Micieli G, Gladis Study Group. Economic benefit from clinical practice guideline compliance in stroke patient management. Health Policy 2004 69 : 305 315
36. Scattoni V, Lazzaro C, Rigatti P. The economics of managing patients with prostate cancer. Arch Ital Urol Androl 2003 75 : 75 87
37. Tariffe delle prestazioni di assistenza ospedaliera per acuti erogate in regime di ricovero ordinario e diurno ex DM 30.06.1997 DRG 337:PROSTATECTOMIA TRANSURETRALE SENZA CC
38. Boletin oficial de la Junta de Andalucia (Boja). 26 Octubre 2005. Consejeria de Salud, Sevilla no. 210a
39. Boletin oficial del estado 179 de 28/7/2006 (BOE). Miniterio de defensa y la generalitat Valenciana, en Valencia, a 12 de junio de 2006.
40. OECD. Country Statistical profiles 2007: Sweden. Available at: http://stats.oecd.org/wbos/viewhtml.aspx?queryname=332&querytype= view&lang=en. Accessed October 2008
41. Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A. First year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer Prostatic Dis 2009 Epub ahead of print [May 26]
42. Inghelmann R, Grande E, Francisci S et al. Regional estimates of prostate cancer burden in Italy. Tumori 2007 93 : 380 386 (Pubitemid 47403454)
43. Robert Koch Institute. Krebsneuerkrankungen in Deutschland. Schätzung Des Robert Koch-Instituts. Available at: htpp://ww.rki.de. Accessed August 2008
44. Globocan Database. The GLOBOCAN 2002 Database. Available at: http://www-Departmentiarc.fr/globocan/database.htm. Accessed October 2008
45. Kraywinkel K, Lehnert M, Semjonow A, Hense HW. Epidemiology of prostate cancer: recent results from the Epidemiological Cancer Register of the District of Münster (Germany). Urologe A 2008 47 : 853 859
46. Institut National du Cancer. Situation de la chimiothérapie des cancers en, 2007. Décembre 2008 : 1 22. Available at: http://www.e-cancer.fr. Accessed October 2008
47. NHS. Reference Costs. Available at: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-082571. Accessed October 2008
48. Molinier L, Bauvin E, Combescure C et al. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health 2008 Epub ahead of print
49. Herkommer K, Fuchs TA, Hautmann RE et al. Radical prostatectomy for men aged <56 years with prostate cancer. Cost of illness analysis. Urologe A 2005 44 : 1183 1188
50. Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997 1 : i vi, 1 53